Thomas S Uldrick
Overview
Explore the profile of Thomas S Uldrick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
101
Citations
3822
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Olivieri D, Gopal A, Uldrick T, Menon M
Cancer Invest
. 2025 Feb;
43(2):141-148.
PMID: 39921375
Background: Human immunodeficiency virus is associated with the development of various aggressive non-Hodgkin B-cell lymphomas (NHL). Despite this, people living with HIV (PLWH) are often excluded from clinical trials. Here...
2.
Ramaswami R, Kask A, DAmico L, Menon M, Lurain K, Yarchoan R, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39915263
Background: CD4 T-cell lymphocytopenia and immune dysfunction are factors that drive the onset and persistence of Kaposi sarcoma (KS) in people with (PWH) and without HIV. Standard chemotherapy agents for...
3.
Lurain K, Ramaswami R, Oksenhendler E, Boutboul D, Dalla Pria A, Ulrich L, et al.
Am J Hematol
. 2025 Jan;
100(3):393-401.
PMID: 39812325
Primary effusion lymphoma (PEL) is an HIV-associated B-cell non-Hodgkin lymphoma (NHL) caused by Kaposi sarcoma herpesvirus (KSHV). There is no validated prognostic model in PEL, and prognosis is thought to...
4.
Zhu M, Madia P, Crawford A, Brouwer-Visser J, Krueger P, Haber L, et al.
Clin Transl Sci
. 2024 Dec;
17(12):e70082.
PMID: 39652449
Ubamatamab, a Mucin 16 (MUC16) × cluster of differentiation 3 (CD3) bispecific antibody that promotes T-cell-mediated cytotoxicity of MUC16-expressing cells, is being investigated for the treatment of ovarian cancer. Intravenous...
5.
Shaik F, Uldrick T, Mazinu M, Gwebushe N, Mosam A
Trop Med Infect Dis
. 2024 Oct;
9(10).
PMID: 39453271
Sub-Saharan Africa bears the largest public health burden of Kaposi sarcoma (KS), a leading cause of cancer mortality. Quality of life (QOL) assessments in cancer patients can provide information on...
6.
Lurain K, Ramaswami R, Ekwede I, Eulo V, Goyal G, Menon M, et al.
J Clin Oncol
. 2024 Oct;
43(4):432-442.
PMID: 39356983
Purpose: Cancer Immunotherapy Trials Network 12 demonstrated safety of pembrolizumab in treating advanced cancer in people with HIV. Here, we report results of the Kaposi sarcoma (KS) cohort. Methods: In...
7.
Marshall V, Cornejo Castro E, Goodman C, Labo N, Liu I, Fisher N, et al.
PLoS Pathog
. 2024 Jul;
20(7):e1012338.
PMID: 39008527
Recently published near full-length KSHV genomes from a Cameroon Kaposi sarcoma case-control study showed strong evidence of viral recombination and mixed infections, but no sequence variations associated with disease. Using...
8.
Ramaswami R, Uldrick T
NEJM Evid
. 2024 May;
3(4):EVIDe2400011.
PMID: 38772003
No abstract available.
9.
Anidi I, Sakai S, Brooks K, Fling S, Wagner M, Lurain K, et al.
Open Forum Infect Dis
. 2024 Apr;
11(5):ofae183.
PMID: 38680611
Blockade of the co-inhibitory receptor PD-1 enhances antitumor responses by boosting the function of antigen-specific T cells. Although rare, PD-1 blockade in patients with cancer can lead to exacerbation of...
10.
Odeny T, Lurain K, Strauss J, Fling S, Sharon E, Wright A, et al.
J Immunother Cancer
. 2023 Nov;
10(9).
PMID: 37935055
Background: The Food and Drug Administration recommends that people living with HIV (PWH) with a CD4+ T cell count (CD4) ≥350 cells/µL may be eligible for any cancer clinical trial,...